301 related articles for article (PubMed ID: 30243823)
1. Cell-permeable NF-κB inhibitor-conjugated liposomes for treatment of glioma.
Zhang Y; Zhang L; Hu Y; Jiang K; Li Z; Lin YZ; Wei G; Lu W
J Control Release; 2018 Nov; 289():102-113. PubMed ID: 30243823
[TBL] [Abstract][Full Text] [Related]
2. Functionalized cell nucleus-penetrating peptide combined with doxorubicin for synergistic treatment of glioma.
Zhang L; Zhang Y; Tai L; Jiang K; Xie C; Li Z; Lin YZ; Wei G; Lu W; Pan W
Acta Biomater; 2016 Sep; 42():90-101. PubMed ID: 27370905
[TBL] [Abstract][Full Text] [Related]
3. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
[TBL] [Abstract][Full Text] [Related]
4. Design of Y-shaped targeting material for liposome-based multifunctional glioblastoma-targeted drug delivery.
Belhadj Z; Ying M; Cao X; Hu X; Zhan C; Wei X; Gao J; Wang X; Yan Z; Lu W
J Control Release; 2017 Jun; 255():132-141. PubMed ID: 28390902
[TBL] [Abstract][Full Text] [Related]
5. Liposome-based glioma targeted drug delivery enabled by stable peptide ligands.
Wei X; Gao J; Zhan C; Xie C; Chai Z; Ran D; Ying M; Zheng P; Lu W
J Control Release; 2015 Nov; 218():13-21. PubMed ID: 26428462
[TBL] [Abstract][Full Text] [Related]
6. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes.
Gao JQ; Lv Q; Li LM; Tang XJ; Li FZ; Hu YL; Han M
Biomaterials; 2013 Jul; 34(22):5628-39. PubMed ID: 23628475
[TBL] [Abstract][Full Text] [Related]
7. Multi-functional peptide-modified liposomes for treatment of glioma.
Park K
J Control Release; 2018 Nov; 289():171. PubMed ID: 30724172
[No Abstract] [Full Text] [Related]
8. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity.
Zhao Y; Ren W; Zhong T; Zhang S; Huang D; Guo Y; Yao X; Wang C; Zhang WQ; Zhang X; Zhang Q
J Control Release; 2016 Jan; 222():56-66. PubMed ID: 26682502
[TBL] [Abstract][Full Text] [Related]
9. Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals.
Zong T; Mei L; Gao H; Cai W; Zhu P; Shi K; Chen J; Wang Y; Gao F; He Q
Mol Pharm; 2014 Jul; 11(7):2346-57. PubMed ID: 24893333
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Lung Cancer by Peptide-Modified Liposomal Irinotecan Endowed with Tumor Penetration and NF-κB Inhibitory Activities.
Hu Y; Zhang Y; Wang X; Jiang K; Wang H; Yao S; Liu Y; Lin YZ; Wei G; Lu W
Mol Pharm; 2020 Oct; 17(10):3685-3695. PubMed ID: 32816496
[TBL] [Abstract][Full Text] [Related]
11. A stabilized peptide ligand for multifunctional glioma targeted drug delivery.
Ying M; Shen Q; Zhan C; Wei X; Gao J; Xie C; Yao B; Lu W
J Control Release; 2016 Dec; 243():86-98. PubMed ID: 27693752
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Combination of Doxorubicin and Paclitaxel Delivered by Blood Brain Barrier and Glioma Cells Dual Targeting Liposomes for Chemotherapy of Brain Glioma.
Chen X; Yuan M; Zhang Q; Ting Yang Y; Gao H; He Q
Curr Pharm Biotechnol; 2016; 17(7):636-50. PubMed ID: 27033513
[TBL] [Abstract][Full Text] [Related]
13. Brain tumor-targeted delivery and therapy by focused ultrasound introduced doxorubicin-loaded cationic liposomes.
Lin Q; Mao KL; Tian FR; Yang JJ; Chen PP; Xu J; Fan ZL; Zhao YP; Li WF; Zheng L; Zhao YZ; Lu CT
Cancer Chemother Pharmacol; 2016 Feb; 77(2):269-80. PubMed ID: 26666650
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
[TBL] [Abstract][Full Text] [Related]
15. Glioma targeted delivery strategy of doxorubicin-loaded liposomes by dual-ligand modification.
Han W; Yin G; Pu X; Chen X; Liao X; Huang Z
J Biomater Sci Polym Ed; 2017 Oct; 28(15):1695-1712. PubMed ID: 28699828
[TBL] [Abstract][Full Text] [Related]
16. Tumor-penetrating peptide functionalization enhances the anti-glioblastoma effect of doxorubicin liposomes.
Yang Y; Yan Z; Wei D; Zhong J; Liu L; Zhang L; Wang F; Wei X; Xie C; Lu W; He D
Nanotechnology; 2013 Oct; 24(40):405101. PubMed ID: 24029287
[TBL] [Abstract][Full Text] [Related]
17. Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model.
Lakkadwala S; Singh J
Colloids Surf B Biointerfaces; 2019 Jan; 173():27-35. PubMed ID: 30261346
[TBL] [Abstract][Full Text] [Related]
18. A novel doxorubicin loaded folic acid conjugated PAMAM modified with borneol, a nature dual-functional product of reducing PAMAM toxicity and boosting BBB penetration.
Xu X; Li J; Han S; Tao C; Fang L; Sun Y; Zhu J; Liang Z; Li F
Eur J Pharm Sci; 2016 Jun; 88():178-90. PubMed ID: 26965003
[TBL] [Abstract][Full Text] [Related]
19. Angiopep-2-conjugated poly(ethylene glycol)-
Lu F; Pang Z; Zhao J; Jin K; Li H; Pang Q; Zhang L; Pang Z
Int J Nanomedicine; 2017; 12():2117-2127. PubMed ID: 28356732
[TBL] [Abstract][Full Text] [Related]
20. RGD-modified PEG-PAMAM-DOX conjugates: in vitro and in vivo studies for glioma.
Zhang L; Zhu S; Qian L; Pei Y; Qiu Y; Jiang Y
Eur J Pharm Biopharm; 2011 Oct; 79(2):232-40. PubMed ID: 21496485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
